JP4150082B2 - 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用 - Google Patents

独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用 Download PDF

Info

Publication number
JP4150082B2
JP4150082B2 JP51191598A JP51191598A JP4150082B2 JP 4150082 B2 JP4150082 B2 JP 4150082B2 JP 51191598 A JP51191598 A JP 51191598A JP 51191598 A JP51191598 A JP 51191598A JP 4150082 B2 JP4150082 B2 JP 4150082B2
Authority
JP
Japan
Prior art keywords
menb
seam
antibodies
antibody
molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51191598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001500372A5 (enExample
JP2001500372A (ja
Inventor
グラノフ，ダン
アール． モエ，グレゴリー
Original Assignee
カイロン コーポレイション
チルドレンズ ホスピタル アンド リサーチ センター アット オークランド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション, チルドレンズ ホスピタル アンド リサーチ センター アット オークランド filed Critical カイロン コーポレイション
Publication of JP2001500372A publication Critical patent/JP2001500372A/ja
Publication of JP2001500372A5 publication Critical patent/JP2001500372A5/ja
Application granted granted Critical
Publication of JP4150082B2 publication Critical patent/JP4150082B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP51191598A 1996-08-27 1997-08-27 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用 Expired - Fee Related JP4150082B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2579996P 1996-08-27 1996-08-27
US60/025,799 1996-08-27
PCT/US1997/015167 WO1998008874A1 (en) 1996-08-27 1997-08-27 Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007221879A Division JP2008044947A (ja) 1996-08-27 2007-08-28 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用

Publications (3)

Publication Number Publication Date
JP2001500372A JP2001500372A (ja) 2001-01-16
JP2001500372A5 JP2001500372A5 (enExample) 2005-04-07
JP4150082B2 true JP4150082B2 (ja) 2008-09-17

Family

ID=21828119

Family Applications (2)

Application Number Title Priority Date Filing Date
JP51191598A Expired - Fee Related JP4150082B2 (ja) 1996-08-27 1997-08-27 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
JP2007221879A Withdrawn JP2008044947A (ja) 1996-08-27 2007-08-28 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007221879A Withdrawn JP2008044947A (ja) 1996-08-27 2007-08-28 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用

Country Status (7)

Country Link
US (4) US6048527A (enExample)
EP (1) EP0922059B1 (enExample)
JP (2) JP4150082B2 (enExample)
AT (1) ATE252602T1 (enExample)
CA (1) CA2264585C (enExample)
DE (1) DE69725739T2 (enExample)
WO (1) WO1998008874A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
WO2002064091A2 (en) * 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
PT939647E (pt) * 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
EP0922059B1 (en) * 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
PT1630168E (pt) 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b
GB9823835D0 (en) * 1998-10-30 1998-12-23 Univ London Component for vaccine
AU760257B2 (en) * 1998-12-14 2003-05-08 Palatin Technologies, Inc. Metallopeptide combinatorial libraries and applications
DE1238102T1 (de) 1999-08-06 2003-05-28 Ivigene Corp., Alachua Mikrobielle polynukleotide, die während der infekton eines wirts exprimiert werden
US7033748B2 (en) * 1999-08-06 2006-04-25 Ivigene Corporation Identification of microbial polynucleotides expressed during infection of a host
US7049398B1 (en) * 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
US7189405B1 (en) * 1999-10-29 2007-03-13 Rice Peter A Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
WO2001036006A1 (en) * 1999-11-19 2001-05-25 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
EP2275129A3 (en) * 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7385025B2 (en) * 2000-12-19 2008-06-10 Palatin Technologies, Inc. Metallopeptide compounds
US20020131953A1 (en) * 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
JP2004529643A (ja) * 2001-04-17 2004-09-30 カイロン コーポレイション 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003089473A1 (en) * 2002-04-19 2003-10-30 Yonsei University Vaccine composition for preventing meningococcal disease
EP1411061A1 (en) 2002-10-16 2004-04-21 Centre National De La Recherche Scientifique (Cnrs) Poly-alpha2,8-sialic acid mimetic peptides and their application
EP2851088A1 (en) * 2003-06-23 2015-03-25 Baxter International Inc. Vaccines against group Y Neisseria meningitidis and meningoccal combinations thereof
UA105492C2 (uk) * 2004-05-11 2014-05-26 Абдженомікс Коеператіеф У.А. Спосіб одержання антитіла для викликання смерті активованих т-клітин, спосіб визначення прийнятної сполуки для викликання смерті активованих т-клітин та фармацевтична композиція
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
JP2008509886A (ja) * 2004-06-23 2008-04-03 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 多糖誘導体および免疫応答の誘導における用途
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
AU2006331634B2 (en) 2005-12-23 2013-01-10 Children's Hospital & Research Center At Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
AR058736A1 (es) * 2005-12-29 2008-02-20 Ct Ingenieria Genetica Biotech Peptidos mimeticos de carbohidratos y su empleo en formulaciones farmaceuticas
US8598337B2 (en) * 2006-01-13 2013-12-03 Baxter International Inc. Method for purifying polysaccharides
GB0606155D0 (en) * 2006-03-28 2006-05-10 Liverpool School Of Tropical M Bacterial vaccine
EP2007427A4 (en) * 2006-04-11 2012-04-04 Yeda Res & Dev IMPROVED VACCINES WITH MULTIMETER HSP60 PEPTIDE SUPPORTS
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2008265767B2 (en) * 2007-06-20 2014-11-13 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
JP5597130B2 (ja) * 2007-07-03 2014-10-01 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸脱ｎ−アセチラーゼの阻害剤及びその使用方法
JP5523313B2 (ja) * 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
WO2009006620A1 (en) 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090156459A1 (en) * 2007-11-16 2009-06-18 Pharmain Corporation Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CA2715272A1 (en) * 2008-03-18 2009-09-24 Merck Sharp & Dohme Corp. A high throughput protein interaction assay
TW201103980A (en) * 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
CA2841752A1 (en) 2011-07-14 2013-06-13 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
JP2015517089A (ja) * 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
WO2014179714A1 (en) * 2013-05-03 2014-11-06 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
JP2023526429A (ja) * 2020-05-19 2023-06-21 ラボラトリー コーポレイション オブ アメリカ ホールディングス 抗体の定量的検出のための方法およびシステム

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
DE3483957D1 (de) * 1983-11-21 1991-02-21 Wellcome Found Komplexe, verfahren zu ihrer herstellung und dieselben enthaltende formulierungen.
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
JP3436756B2 (ja) * 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
BR9007917A (pt) * 1989-12-14 1992-10-20 Ca Nat Research Council Vacina aperfeicoada de conjugado polissacaridico meningogocico
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
EP0922059B1 (en) 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
PT1630168E (pt) 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b

Also Published As

Publication number Publication date
CA2264585A1 (en) 1998-03-05
US7063949B2 (en) 2006-06-20
US6642354B2 (en) 2003-11-04
US20060035284A1 (en) 2006-02-16
US20040077840A1 (en) 2004-04-22
ATE252602T1 (de) 2003-11-15
EP0922059B1 (en) 2003-10-22
US20020197260A1 (en) 2002-12-26
CA2264585C (en) 2005-06-14
US6048527A (en) 2000-04-11
EP0922059A1 (en) 1999-06-16
WO1998008874A1 (en) 1998-03-05
JP2001500372A (ja) 2001-01-16
JP2008044947A (ja) 2008-02-28
US7504254B2 (en) 2009-03-17
DE69725739T2 (de) 2004-08-05
DE69725739D1 (de) 2003-12-11

Similar Documents

Publication Publication Date Title
JP4150082B2 (ja) 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
JP4295431B2 (ja) 髄膜炎菌性ｂエピトープの分子模倣物
JP5215275B2 (ja) 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
Moe et al. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease
JP2004526418A (ja) ワクチンの成分
Rukavina et al. Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection
Beninati et al. Protective immunization against group B meningococci using anti-idiotypic mimics of the capsular polysaccharide
Park et al. Peptide mimotopes of Neisseria meningitidis group B capsular polysaccharide
RU2355704C2 (ru) Моноклональное антитело, направленное против gna33 пептида, и его применение
US7250164B2 (en) Vaccine composition for preventing meningococcal disease
US20060062779A1 (en) Methods and compositions relating to mannuronic acid specific binding peptides
CN101638433A (zh) 保守淋球菌表位的拟肽及应用它们的方法和组合物
Biondo et al. Protective Immunization against
HK1141034B (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070828

A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20070828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080610

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080627

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110704

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110704

Year of fee payment: 3

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110704

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110704

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120704

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120704

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130704

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees